255 related articles for article (PubMed ID: 15930601)
1. The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer.
Tilly N; Johansson J; Isacsson U; Medin J; Blomquist E; Grusell E; Glimelius B
Phys Med Biol; 2005 Jun; 50(12):2765-77. PubMed ID: 15930601
[TBL] [Abstract][Full Text] [Related]
2. Significance and implementation of RBE variations in proton beam therapy.
Paganetti H
Technol Cancer Res Treat; 2003 Oct; 2(5):413-26. PubMed ID: 14529306
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver.
Carabe A; España S; Grassberger C; Paganetti H
Phys Med Biol; 2013 Apr; 58(7):2103-17. PubMed ID: 23470339
[TBL] [Abstract][Full Text] [Related]
5. Variations in the RBE for cell killing along the depth-dose profile of a modulated proton therapy beam.
Britten RA; Nazaryan V; Davis LK; Klein SB; Nichiporov D; Mendonca MS; Wolanski M; Nie X; George J; Keppel C
Radiat Res; 2013 Jan; 179(1):21-8. PubMed ID: 23148508
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
Ödén J; Eriksson K; Toma-Dasu I
Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
[TBL] [Abstract][Full Text] [Related]
7. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
Mock U; Bogner J; Georg D; Auberger T; Pötter R
Strahlenther Onkol; 2005 Jul; 181(7):448-55. PubMed ID: 15995838
[TBL] [Abstract][Full Text] [Related]
8. Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in Orsay.
Calugaru V; Nauraye C; Noël G; Giocanti N; Favaudon V; Mégnin-Chanet F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1136-43. PubMed ID: 21075549
[TBL] [Abstract][Full Text] [Related]
9. [Dosimetric analysis of radiotherapy with middle shielding blocks of different widths at the lower cervical supraclavicular field for stage N2-3 nasopharyngeal carcinoma].
Li FM; Luo W; He ZC; Zhang L; Sun Y; Qin WJ; Lu LX; Han F; Liu XQ; Liu MZ
Ai Zheng; 2007 Oct; 26(10):1127-32. PubMed ID: 17927886
[TBL] [Abstract][Full Text] [Related]
10. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
11. Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment.
Chaudhary P; Marshall TI; Perozziello FM; Manti L; Currell FJ; Hanton F; McMahon SJ; Kavanagh JN; Cirrone GA; Romano F; Prise KM; Schettino G
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):27-35. PubMed ID: 24986743
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of biologically optimized spread-out bragg peaks for protons and carbon ions.
Wilkens JJ; Oelfke U
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):262-6. PubMed ID: 17935903
[TBL] [Abstract][Full Text] [Related]
13. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
[TBL] [Abstract][Full Text] [Related]
14. Radiobiological intercomparison of the 160 MeV and 230 MeV proton therapy beams at the Harvard Cyclotron Laboratory and at Massachusetts General Hospital.
Wouters BG; Skarsgard LD; Gerweck LE; Carabe-Fernandez A; Wong M; Durand RE; Nielson D; Bussiere MR; Wagner M; Biggs P; Paganetti H; Suit HD
Radiat Res; 2015 Feb; 183(2):174-87. PubMed ID: 25587741
[TBL] [Abstract][Full Text] [Related]
15. Application of constant vs. variable relative biological effectiveness in treatment planning of intensity-modulated proton therapy.
Frese MC; Wilkens JJ; Huber PE; Jensen AD; Oelfke U; Taheri-Kadkhoda Z
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):80-8. PubMed ID: 20382482
[TBL] [Abstract][Full Text] [Related]
16. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques.
Longobardi B; De Martin E; Fiorino C; Dell'oca I; Broggi S; Cattaneo GM; Calandrino R
Radiother Oncol; 2005 Nov; 77(2):148-56. PubMed ID: 16260056
[TBL] [Abstract][Full Text] [Related]
17. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in α/β.
Paganetti H
Acta Oncol; 2017 Nov; 56(11):1379-1386. PubMed ID: 28918679
[TBL] [Abstract][Full Text] [Related]
18. Relative biological effectiveness (RBE) values for proton beam therapy.
Paganetti H; Niemierko A; Ancukiewicz M; Gerweck LE; Goitein M; Loeffler JS; Suit HD
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):407-21. PubMed ID: 12023146
[TBL] [Abstract][Full Text] [Related]
19. A treatment planning comparison of combined photon-proton beams versus proton beams-only for the treatment of skull base tumors.
Feuvret L; Noel G; Weber DC; Pommier P; Ferrand R; De Marzi L; Dhermain F; Alapetite C; Mammar H; Boisserie G; Habrand JL; Mazeron JJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):944-54. PubMed ID: 17889276
[TBL] [Abstract][Full Text] [Related]
20. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study.
Mu X; Björk-Eriksson T; Nill S; Oelfke U; Johansson KA; Gagliardi G; Johansson L; Karlsson M; Zackrisson DB
Acta Oncol; 2005; 44(6):554-62. PubMed ID: 16165914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
